sellNotable cluster of 2
Goldman Sachs Group Inc sold $2.3M of ATTO
other at Attovia Therapeutics, Inc.. 105,807 shares at an average of $21.28, traded Aug 5, 2026, filed Aug 28, 2026.
Warning score
61Value
$2.3M
105,807 shares
Holdings after
0
-124% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +8RoleOther
- +25Trade size$2.3M at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
ATTOOct 12, 2026 · close 14.59
Since filing Aug 28, 2026: -29.5%SPY +1.4% · excess -30.9%
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000886982-26-000522, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | POpen-market purchase Common Stockindirect: See Footnotes | +85,000 | $21.00 | $1.8M | 85,000 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -988 | $22.03 | $22k | 84,012 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -447 | $21.87 | $9,776 | 83,565 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -1,332 | $22.03 | $29k | 82,233 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 82,033 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -1,556 | $22.06 | $34k | 80,477 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -3,402 | $22.02 | $75k | 77,075 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.10 | $4,420 | 76,875 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -480 | $21.55 | $10k | 76,395 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $22.11 | $2,211 | 76,295 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -753 | $21.97 | $17k | 75,542 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -672 | $22.02 | $15k | 74,870 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -6,970 | $22.03 | $154k | 67,900 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -400 | $22.02 | $8,808 | 67,500 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -1,180 | $21.84 | $26k | 66,320 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -1,040 | $22.05 | $23k | 65,280 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -300 | $20.84 | $6,252 | 64,980 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -443 | $21.78 | $9,649 | 64,537 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 64,337 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -700 | $22.07 | $15k | 63,637 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -1,163 | $22.19 | $26k | 62,474 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $21.99 | $2,199 | 62,374 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -6,763 | $21.61 | $146k | 55,611 | Aug 28, 2026 |
| Aug 5, 2026 | SOpen-market sale Common Stockindirect: See Footnotes | -76,418 | $21.04 | $1.6M | 0 | Aug 28, 2026 |
| Aug 6, 2026 | CConversion Common Stockindirect: See Footnotes | +1,957,134 | $0.00 | $0 | 2,042,134 | Aug 28, 2026 |
| Aug 6, 2026 | CConversion Common Stockindirect: See Footnotes | +478,498 | $0.00 | $0 | 2,520,632 | Aug 28, 2026 |
| Aug 6, 2026 | POpen-market purchase Common Stockindirect: See Footnotes | +500,000 | $17.00 | $8.5M | 3,020,632 | Aug 28, 2026 |
| Aug 6, 2026 | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -18,181,830 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Aug 6, 2026 | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -4,445,275 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Aug 5, 2026 | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +2,872 | $21.22 | $61k | 2,872 | Aug 28, 2026 |
| Aug 5, 2026 | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +28,717 | $21.22 | $609k | 31,589 | Aug 28, 2026 |
| Aug 5, 2026 | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +11,488 | $21.22 | $244k | 43,077 | Aug 28, 2026 |
| Aug 5, 2026 | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +45,588 | $21.27 | $970k | 88,665 | Aug 28, 2026 |
| Aug 5, 2026 | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +11,398 | $21.27 | $242k | 100,063 | Aug 28, 2026 |
| Aug 5, 2026 | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +5,744 | $21.22 | $122k | 105,807 | Aug 28, 2026 |
Related signals
Other insiders at Attovia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $10M 585,000 shares | - | |
| 63Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $10M 585,000 shares | - | |
| 68Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $2.3M 105,807 shares | -124% | |
| 56Moderate | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $10M 585,000 shares | - | |
| 61Notable | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $2.3M 105,807 shares | -124% | |
| 63Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $10M 585,000 shares | - | |
| 68Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $2.3M 105,807 shares | -124% | |
| 50Moderate | Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | $6.5M 382,352 shares | +10% | |
| 52Moderate | Attovia Therapeutics, Inc. | Redmile Group, LLC owner | $10M 600,000 shares | +77% | |
| 53Moderate | Attovia Therapeutics, Inc. | Sanofi owner | $5.1M 300,000 shares | +38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.